Effect of topotecan on retinocytoma cell apoptosis and expression of Livin and PTEN

Chinese Medical Journal

Volumn 126, Issue 2, 2013, Pages 340-344

  Zhang, Meng ^a   Shan, Bao En ^a   Yuan, Nai Fen ^a   Liu, Wei ^a  

^a Hebei Provincial Tumor Hospital   (China)

Author keywords

Flow cytometry; Immunohistochemistry; Livin; PTEN; Retinocytoma; Western blotting

Indexed keywords

LIVIN; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; TOPOTECAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESCHOOL CHILD; PROTEIN EXPRESSION; RETINOBLASTOMA; SCHOOL CHILD; SURVIVAL RATE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; INHIBITOR OF APOPTOSIS PROTEINS; MALE; NEOPLASM PROTEINS; PTEN PHOSPHOHYDROLASE; RETINAL NEOPLASMS; RETINOBLASTOMA; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84872728206     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122480     Document Type: Article

References (19)

1. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol 1990; 108: 128-132.
2. Leal-Leal C, Flores-Rojo M, Medina-Sansón A, Cerecedo-Díaz F, Sánchez-Félix S, González-Ramella O, et al. A multicentre report from the Mexican Retinoblastoma Group. Br J Ophthalmol 2004; 88: 1074-1077.
3. Wilson MW, Haik BG, Liu T, Merchant TE, Rodriguez-Galindo C. Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma. Am J Ophthalmol 2005; 140: 397.
4. Olaussen KA, Soria JC, Morat L, Martin A, Sabatier L, Morere JF, et al. Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. Anticancer Res 2003; 23: 4885-4890.
5. Hariu H, Hirohashi Y, Torigoe T, Asanuma H, Hariu M, Tamura Y, et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res 2005; 11: 1000-1009.
6. Yagihashi A, Asanuma K, Tsuji N, Torigoe T, Sato N, Hirata K, et al. Detection of anti-Livin antibody in gastrointestinal cancer patients. Clin Chem 2003; 49: 1206-1208.
7. Chen L, Ren GS, Li F, Sun SQ. Expression of Livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma. World J Gastroenterol 2008; 14: 5749-5754.
8. Crnković-Mertens I, Wagener N, Semzow J, Gröne EF, Haferkamp A, Hohenfellner M, et al. Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci 2007; 64: 1137-1144.
9. Crnković-Mertens I, Muley T, Meister M, Hartenstein B, Semzow J, Butz K, et al. The anti-apoptotic Livin gene is an important determinant for the apoptotic resistance of non-small cell lung cancer cells. Lung Cancer 2006; 54: 135-142.
10. Goncharuk VN, del-Rosario A, Kren L, Anwar S, Sheehan CE, Carlson JA, et al. Co-down regulation of PTEN, KAI-1, and nm23-H1 tumor/metastasis suppressor proteins in non-small cell lung cancer. Ann Diagn Pathol 2004; 8: 6-16.
11. Olaussen KA, Soria JC, Morat L, Martin A, Sabatier L, Morere JF, et al. Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. Anticancer Res 2003; 23: 4885-4890.
12. Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R, et al. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 2002; 33: 405-409.
13. Chen ST, Yu SY, Tsai M, Yeh KT, Wang JC, Kao MC, et al. Mutation analysis of the putative tumor suppression gene PTEN/MMAC1 in sporadic breast cancer. Breast Cancer Res Treat 1999; 55: 85-89.
14. Chalhoub N, Zhu G, Zhu X, Baker SJ. Cell type specificity of PI3K signaling in Pdk1-and PTEN-deficient brains. Genes Dev 2009; 23: 1619-1624.
15. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 1998; 105: 573-580.
16. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682-1687.
17. Rodriguez-Galindo C, Wilson MW, Haik BG, Merchant TE, Billups CA, Shah N, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003; 21: 2019-2025.
18. Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 1999; 5: 3617-3631.
19. Chantada GL, Fandino AC, Casak SJ, Mato G, Manzitti J, Schvartzman E. Activity of topotecan in retinoblastoma. Ophthalmic Genet 2004; 25: 37-43.